ASCO GI 2023 | QoL analyses from RATIONALE-301 of tislelizumab vs sorafenib in HCC

Richard Finn, MD, University of California, Los Angeles, CA, comments on the health-related quality of life (QoL) in patients from the Phase III RATIONALE 301 trial (NCT03412773). The trial assessed first-line tislelizumab, an anti-PD-L1 monoclonal antibody, versus sorafenib in previously untreated patients with unresectable hepatocellular carcinoma (HCC). Tislelizumab demonstrated better overall survival rates and provided better QoL for patients over sorafenib. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.